Company Overview
Talphera, Inc. operates as a specialty pharmaceutical company dedicated to the development and commercialization of therapies intended for use within medically supervised settings. The firm functions within the broader Healthcare sector, specifically classified under the industry of Drug Manufacturers - Specialty & Generic, which implies a focus on niche therapeutic areas and often smaller-scale production compared to broad-spectrum manufacturers. The company currently maintains a market capitalization of $37.11M, while its annual revenue for the trailing twelve months stands at $28,000. The employee count is listed as N/A in available data, indicating that specific headcount details are not currently disclosed for public reporting. These financial figures highlight the company's position as a micro-cap entity with minimal revenue generation relative to its market valuation, suggesting a capital-intensive development phase where the market capitalization significantly exceeds the revenue base, a common characteristic for firms investing heavily in research and development prior to commercial product launch.
Financial Health
The financial statements for Talphera, Inc. reveal a trailing twelve-month revenue of $28,000, a net income of $-14,363,000, and an EBITDA metric that is not available due to the company's reporting status. The substantial gap between the negligible revenue of $28,000 and the net loss of $-14,363,000 indicates a cost structure dominated by high operating expenses, likely driven by research and development activities or clinical trial costs that far outpace current sales. The company reports a free cash flow of $-6,531,500, which signifies a continuous burn rate where cash outflows for operations and capital expenditures exceed cash inflows, limiting immediate financial flexibility without external financing. Margin analysis shows a gross margin of 0.0%, an operating margin of -48157.1%, and a profit margin of 0.0%, reflecting that the company is not yet profitable on a per-unit basis and is operating at a significant loss before interest, taxes, and non-recurring items. Regarding leverage, the company holds $20.38M in cash against $6.50M in debt, resulting in a debt-to-equity ratio of 38.15, which suggests a balance sheet that is currently net cash positive despite the high debt-to-equity multiple often seen in early-stage biotech firms. The current ratio stands at 5.49, indicating a robust short-term liquidity position where current assets significantly exceed current liabilities, providing a wide buffer against short-term obligations. Return metrics show a return on equity of -114.7% and a return on assets of -35.1%, revealing that management is currently destroying value from the perspective of shareholders and total assets due to the net loss position rather than generating returns on the capital base.
Valuation Assessment
Valuation metrics for Talphera, Inc. present a complex picture with a trailing P/E ratio of N/A and a forward P/E of -2.65. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the company does not yet generate positive earnings, and the forward metric reflects expectations of potential future earnings per share that have not yet materialized in historical data. The price-to-book ratio is recorded at 2.15, indicating that the market values the company at a premium of over double its net book value, a valuation often seen in biotech firms where intangible assets and pipeline potential are priced higher than tangible assets. Alternative valuation metrics include a price-to-sales ratio of 1325.43 and an EV/EBITDA of N/A, suggesting that traditional earnings-based valuation models are inapplicable and that investors are pricing the stock based on pipeline potential and sales multiples rather than current profitability. The stock trades within a specific range with a 52-week high of $1.57 and a 52-week low of $0.38. Without a specific current price provided in the facts to calculate an exact percentage, the valuation relative to this range is determined by these established high and low points which define the recent volatility boundaries for the security. The beta value is 0.49, indicating that the stock's price volatility is less than half that of the broader market, suggesting a lower sensitivity to general market movements compared to large-cap equities.
Growth & Income
Growth metrics for Talphera, Inc. show revenue growth year-over-year as N/A and earnings growth year-over-year as N/A, as the company does not report comparable prior-year data in the provided financials. The inability to calculate year-over-year growth rates implies that the company is in an early stage of commercialization where historical growth trajectories have not yet been established for standard analysis. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, indicating that all available earnings, or rather the retention of capital, are directed back into the business operations and development pipeline rather than distributed to shareholders. Consequently, the overall growth and income profile for Talphera, Inc. is characterized by zero current income distribution and a reliance on capital markets to fund growth initiatives in the absence of organic profitability or dividend generation.